The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Cartesian Therapeutics Inc shares valued at $101,968 were purchased by SPRINGER TIMOTHY A on Aug 12 ’24. At $12.72 per share, SPRINGER TIMOTHY A acquired 8,016 shares. The insider’s holdings grew to 11,509 shares worth approximately $0.26 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, BARABE TIMOTHY C purchased 7,500 shares, netting a total of over 95,250 in proceeds. Following the buying of shares at $12.70 each, the insider now holds 21,766 shares.
Before that, SPRINGER TIMOTHY A had added 4,800 shares to its account. In a trade valued at $3,187, the Director bought Cartesian Therapeutics Inc shares for $0.66 each. Upon closing the transaction, the insider’s holdings increased to 4,800 shares, worth approximately $2.17 million.
As published in their initiating research note from TD Cowen on August 06, 2024, Cartesian Therapeutics Inc [RNAC] has been a Buy. Analysts at Oppenheimer downgraded the stock from ‘”an Outperform”‘ to ‘”a Perform”‘ outlook in a report released in early July. As of June 04, 2024, Oppenheimer has initiated its “an Outperform” rating for RNAC. Earlier on May 24, 2024, Mizuho initiated its rating. Their recommendation was “a Buy” for RNAC stock.
Analyzing RNAC Stock Performance
During the last five days, there has been a surge of approximately 31.45%. Over the course of the year, Cartesian Therapeutics Inc shares have jumped approximately 10.34%. Shares of the company reached a 52-week high of $41.87 on 06/06/24 and a 52-week low of $11.66 on 04/08/24. A 50-day SMA is recorded $15.19, while a 200-day SMA reached $20.24. Nevertheless, trading volume fell to 0.5 million shares from 0.23 million shares the previous day.
Support And Resistance Levels for Cartesian Therapeutics Inc (RNAC)
According to the 24-hour chart, there is a support level at 19.24, which, if violated, would cause prices to drop to 15.66. In the upper region, resistance lies at 24.85. The next price resistance is at 26.88. RSI (Relative Strength Index) is 73.21 on the 14-day chart, showing overbought technical sentiment. Moving Average Convergence Divergence (MACD) is at 2.40, which suggests the price will increase in the coming days. Percent R is at 5.16%, indicating bullish price movement. Stochastics %K at selling indicates that the stock is to be held.
Which companies own the most shares of Cartesian Therapeutics Inc (RNAC)?
On April 23, 2024, H.C. Wainwright assigned a price target of “a Buy” to the stock and reiterated coverage with a $54.
